ClinicalTrials.gg
RecruitingNCT06788171Updated Oct 1, 2026

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

A Phase 2 interventional study of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy and Bevacizumab in Colorectal Cancer Liver Metastasis, sponsored by Fujian Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Fujian Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 1, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 231 studies testing bevacizumab in Colorectal Neoplasms — 50 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
163rd of 225
35 · median 62
Started
2026
with 12 others
Phase 2
134 of 231
32 open now
Primary completion
2027-09
later than 36 of 60 live
Registered
208th of 231
by date

Among the 231 studies testing bevacizumab in Colorectal Neoplasms, this one is the 163rd largest by planned enrollment of the 225 interventional ones that give a count, is one of 13 that started in 2026, is one of 134 in phase 2, reaches primary completion later than 36 of the 60 other live ones, and was the 208th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

50 of the 231 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 50 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM

03

Conditions studied

  • Colorectal Cancer Liver Metastasis
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years, any gender.
  2. confirmed colorectal adenocarcinoma with liver from colorectal cancer.
  3. (ECOG) performance status 0-1.
  4. Adequate organ function, no to radiotherapy, or immunotherapy.
  5. Estimated of more than 3 months.
  6. No obvious indications for emergent surgery due to primary tumor bleeding, obstruction, or similar conditions.
  7. At least one radiographically per (RECIST) version 1.1.
  8. Microsatellite/mismatch repair status MSS/pMMR.
  9. No prior anti-tumor therapy for colorectal cancer, including radiotherapy, chemotherapy, or surgery.
  10. No prior immunotherapy.
  11. Women of or men with partners of childbearing potential agree to use highly effective (annual failure rate \<1%) from 7 days before the first dose through 24 weeks after the last dose.
  12. Ability and willingness to comply with study visits, treatment schedules, laboratory testing, and other protocol-specified procedures throughout the study.
  13. Signed written .

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Pathological diagnosis of signet ring cell carcinoma.
  3. History of other within the past 5 years, except cured skin cancer and cervical carcinoma in situ.
  4. Uncontrolled epilepsy, central nervous system disorders, or history of psychiatric disorders that, in the opinion of the investigator, may interfere with signing the form or affect patient compliance with oral medication.
  5. (i.e., active) cardiac disease, such as symptomatic coronary artery disease, (NYHA) Class II or greater congestive heart failure, or significant arrhythmias requiring drug intervention (see Appendix 12), or history of myocardial infarction within the past 12 months.
  6. Organ transplant recipients requiring therapy and long-term users.
  7. Patients with diseases.
  8. Severe uncontrolled recurrent infections or other severe uncontrolled comorbidities.
  9. Subjects with baseline hematological and biochemical parameters not meeting the following criteria: ≥90g/L; (ANC) .≥1.5×10\^9/L; ≥100×10\^9/L; , AST ≤2.5 times the ; ALP ≤2.5 times the upper limit of normal; serum total \<1.5 times the upper limit of normal; serum creatinine \<1 times the upper limit of normal; serum albumin ≥30g/L.
  10. Known deficiency of dihydropyrimidine dehydrogenase (DPD).
  11. Allergy to any drug components.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    PULSAR combined with PD-1 Ab and Bevacizumab plus Chemotherapy

    Interventions: 1. Radiation: PULSAR(Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy) 2. Drug: Bevacizumab 3. Drug: Capecitabine 4. Drug: Oxaliplatin 5. Drug: Sintilimab

    Radiation: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy · Drug: Bevacizumab · Drug: Capecitabine · Drug: Oxaliplatin · Drug: Sintilimab

Interventions

  • RadiationPersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy

    PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.

  • Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.

  • Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.

  • Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.

  • Sintilimab: 200mg, d1, q3w, 6 cycles.

06

What researchers measure

Primary outcomes

  1. Progression-free-Survival

    Time frame: From enrollment to 36 month

Secondary outcomes

  1. Adverse Reactions

    Time frame: From enrollment to 36 month

  2. Overall Survival (OS)

    Time frame: From enrollment to 36 month

  3. Objective Response Rate (ORR)

    Time frame: From enrollment to 36 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 15 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Mar 2025 → May 2026, primary completion Dec 2026 → Sep 2027 and completion Dec 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 23, 2025
StartActual
May 9, 2026was Mar 2025
Primary completionEst.
Sep 1, 2027was Dec 2026
CompletionEst.
Sep 1, 2027was Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
Fujian Cancer Hospital is now Recruiting
Oct 1, 2026
Start date
Mar 1, 2025→May 9, 2026 (actual)
Oct 1, 2026
Primary completion
Dec 1, 2026→Sep 1, 2027
Oct 1, 2026
Study completion
Dec 1, 2026→Sep 1, 2027
Oct 1, 2026
Eligibility
3 inclusion criteria edited, 5 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedPathologically confirmed colorectal canceradenocarcinoma with liver metastases (stage M1)from colorectal cancer.
  • ChangedBefore Karnofsky Performance Status ≥70.Now Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • AddedEstimated life expectancy of more than 3 months.
  • AddedNo obvious indications for emergent surgery due to primary tumor bleeding, obstruction, or similar conditions.
  • AddedAt least one radiographically measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  • ChangedBefore No prior chemotherapy or any other anti-tumor treatment before inclusion.Now No prior anti-tumor therapy for colorectal cancer, including radiotherapy, chemotherapy, or surgery.
  • RemovedAbility to comply with the study protocol during the study period.
  • AddedWomen of childbearing potential or men with partners of childbearing potential agree to use highly effective contraception (annual failure rate <1%) from 7 days before the first dose through 24 weeks after the last dose.
  • AddedAbility and willingness to comply with study visits, treatment schedules, laboratory testing, and other protocol-specified procedures throughout the study.
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    Fujian Cancer Hospital is now Recruiting
    Start date Mar 1, 2025→May 9, 2026 (now actual)
    Primary completion Dec 1, 2026→Sep 1, 2027
    Study completion Dec 1, 2026→Sep 1, 2027
    Eligibility 3 inclusion criteria edited, 5 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedPathologically confirmed colorectal canceradenocarcinoma with liver metastases (stage M1)from colorectal cancer.
    • ChangedBefore Karnofsky Performance Status ≥70.Now Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
    • AddedEstimated life expectancy of more than 3 months.
    • AddedNo obvious indications for emergent surgery due to primary tumor bleeding, obstruction, or similar conditions.
    • AddedAt least one radiographically measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    • ChangedBefore No prior chemotherapy or any other anti-tumor treatment before inclusion.Now No prior anti-tumor therapy for colorectal cancer, including radiotherapy, chemotherapy, or surgery.
    • RemovedAbility to comply with the study protocol during the study period.
    • AddedWomen of childbearing potential or men with partners of childbearing potential agree to use highly effective contraception (annual failure rate <1%) from 7 days before the first dose through 24 weeks after the last dose.
    • AddedAbility and willingness to comply with study visits, treatment schedules, laboratory testing, and other protocol-specified procedures throughout the study.
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06788171
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
May 9, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Sha Huang, MD
Contact
huangsha0210@163.com
+86-13763820570
Jinluan Li, MD
Contact
lijinluan@fjmu.edu.cn
+86-15159628678

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion